Close Menu

NEW YORK (GenomeWeb) – Japan’s Ministry of Health, Labor and Welfare approved Roche's entrectinib (Rozlytrek) for the treatment of adult and pediatric patients with NTRK fusion-positive, advanced recurrent solid tumors.

This is the first pan-cancer drug approved for NTRK-positive solid tumors by Japanese health regulators and has been granted Sakigake designation (akin to breakthrough designation in the US) and orphan drug designation. The drug is also under review for advanced non-small cell lung cancer patients with ROS1 fusions.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.